COMMUNIQUÉS West-GlobeNewswire

La FDA accorde le statut de médicament orphelin à CLLS52 (alemtuzumab) de Cellectis pour le traitement de la LLA
01/08/2024
NEW YORK, 01 août 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN [...]
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
01/08/2024
● Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ● Q2 Test volume up 12% year-over-year to record levels ● Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ● Q2 Volume, Revenue [...]
The Pennant Group Announces New $250 Million Credit Facility
01/08/2024
EAGLE, Idaho, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced that the [...]
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
01/08/2024
Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential [...]
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
01/08/2024
WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies [...]
CooperCompanies Acquires obp Surgical, Expanding CooperSurgical’s Portfolio of Leading Medical Devices
01/08/2024
SAN RAMON, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), today announced that CooperSurgical has acquired obp Surgical, a U.S.-based medical device company with a suite of single-use cordless [...]
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
01/08/2024
Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 VANCOUVER, British Columbia, Aug. 01, 2024 ( [...]
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
01/08/2024
– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO ® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial evaluating petosemtamab [...]
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
01/08/2024
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced [...]
Merit Medical Reports Second Quarter 2024 Results and Raises Full-Year Guidance
01/08/2024
Second Quarter 2024 Highlights† Reported revenue of $338.0 million, up 5.6% Constant currency revenue* up 6.6% Constant currency revenue, organic,* up 5.0% GAAP operating margin of 13.6%, compared to 9.0% in prior year [...]
INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update
01/08/2024
Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company [...]
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
01/08/2024
Second quarter total revenue of $147 million, Crysvita ® revenue of $114 million and Dojolvi ® revenue of $19 million Increased 2024 expected total revenue guidance to $530 million to $550 million NOVATO, Calif., Aug. [...]
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01/08/2024
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent [...]
LeMaitre Q2 2024 Financial Results
01/08/2024
BURLINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided [...]
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
01/08/2024
LAUSANNE, Switzerland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company [...]
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
01/08/2024
Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in [...]
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
01/08/2024
Year-over-year revenue grows 9% , operating profit up 38% , non-GAAP operating profit up 30% Operating cash flow of $440 million Quarterly dividend increases 10% to $0.53 per share Company to host an Investor Day on [...]
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
01/08/2024
Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an [...]
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
01/08/2024
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will [...]

Pages